Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Takeda Pharmaceutical revenue increased from ¥2.1 trillion in 2019 to ¥3.3 trillion in 2020, a (56.9%) increase.

Annual Revenue (¥)

Takeda Pharmaceutical revenue was ¥3.29 t in FY, 2020 which is a (56.9%) year over year increase from the previous period.

FY, 2018FY, 2019FY, 2020
Revenue¥1.77 t¥2.1 t¥3.29 t

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Geographic Segment

Takeda Pharmaceutical revenue breakdown by business segment: 13.3% from Neuroscience, 12.8% from Oncology, 12.0% from PDT Immunology, 10.2% from Rare Hematology, 5.2% from Rare Metabolic, 21.2% from Gastroenterology and 25.4% from Other

Takeda Pharmaceutical revenue breakdown by geographic segment: 5.0% from Asia (excluding Japan), 19.6% from Europe and Canada, 48.5% from United States, 18.0% from Japan and 8.9% from Other

FY, 2018FY, 2019FY, 2020
Other780.9 b704.8 b
Neuroscience154.7 b438.5 b
Oncology399.4 b421 b
PDT Immunology93.5 b394.2 b
Hereditary Angioedema20.4 b129.8 b
Rare Hematology66.7 b334.2 b
Rare Metabolic42.3 b170.8 b
Gastroenterology539.3 b697.9 b
Royalty and Service Income76.69 b
Sales of Pharmaceutical Products1.69 t
FY, 2018FY, 2019FY, 2020
Other30.19 b38.3 b71.3 b
Asia (excluding Japan)104.03 b105.4 b165.4 b
Latin America75.66 b88.1 b143.5 b
Russia/CIS68.24 b59.7 b76.8 b
Europe and Canada313.72 b405.6 b645.5 b
United States598.34 b829 b1.6 t
Japan580.35 b571 b592.8 b

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu